Lowell, MA – October 30, 2018 – Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the appointment of Sean Wirtjes as Chief Financial Officer. He reports directly to the company’s CEO, Robert Spignesi, and replaces Richard Kollender, who has rejoined the company’s Board of Directors.
Wirtjes has over 25 years of broad financial experience in the healthcare and technology industries. Most recently, he served as Vice President, Finance and Controller of Asia Pacific, Middle East and Africa (AMEA) for Boston Scientific, a manufacturer of medical devices. In this role, he led all aspects of financial management for the AMEA region, as well as providing regional oversight for the strategic pricing, reimbursement, supply chain, and business development functions. Prior to that, he served as Vice President of Investor Relations at Boston Scientific, in progressive roles at Varian, Inc. including Vice President and Controller and Vice President, Finance and Treasurer, and as Corporate Controller at Quova. Wirtjes began his career with PricewaterhouseCoopers, serving emerging, high-growth clients across the healthcare and technology industries.
“I am delighted to welcome Sean to our executive management team,” said Spignesi. “He brings significant global financial and business experience to the company and will be instrumental in our continued growth and success.”
“I am thrilled to join Rapid Micro Biosystems at such an exciting time in the company’s development,” said Wirtjes. “I look forward to working closely with Rob and the leadership team to build on the success of the Growth DirectTM System, accelerate the company’s growth trajectory and create value for our customers and shareholders.”
Wirtjes holds a BS in Accounting from the Carroll School of Management at Boston College. He is a Certified Public Accountant and a member of Financial Executives International (FEI) and the Association of Financial Professionals (AFP).
About Rapid Micro Biosystems
Rapid Micro Biosystems delivers the Growth Direct™ System, an automated, non-destructive rapid detection and enumeration technology based on the compendial method for microbial quality control in pharmaceutical manufacturing. The system automates and accelerates detection and enumeration in sterility testing, environmental monitoring, and bioburden testing, eliminating manual steps and analysis. The detection technology, first developed and patented by Dr. Don Straus, Ph.D., uses the natural auto-fluorescence of microbes and requires no reagents. For more information visit www.rapidmicrobio.com.